States split on the HHS peptide policy: Utah follows it, medical boards are told it changes no state law
The day HHS published its peptide enforcement policy, Utah said it would match it. On November 10 the Federation of State Medical Boards told boards the opposite lesson: federal non enforcement does not amend state law or board authority.
On October 30, 2026 Utah's Division of Professional Licensing said it will exercise similar limited enforcement discretion in Utah, in strict accordance with the scope of the HHS interim policy, and only when each HHS condition is met.
On November 10 the Alabama Board of Medical Examiners published an FSMB FAQ on the same policy. It says the policy does not amend state practice acts or direct boards to suspend enforcement; that a state requirement of 503A compliance should not be treated as met just because a compounder follows the HHS policy; that physicians who compound face the same conditions as pharmacies; and that the policy names no state recipient, deadline or process for the reports it requires. It lists the Alabama, Mississippi and South Carolina research grade peptide notices as current board positions.
- Pharmacies compounding any of the six peptides for patients in Utah or Alabama.
- Nonresident pharmacies shipping peptides into states that have not spoken.
- Prescribers and telehealth programs relying on the federal policy alone.
Utah's position covers Utah licensees. The FSMB FAQ is guidance to medical boards, not a rule, but it sets out how boards are being told to read the federal policy. Other states have not yet said where they stand.
| Source published | October 30, 2026 | Utah DOPL announcement. |
|---|---|---|
| Source published | November 10, 2026 | FSMB FAQ dated November 10, published by the Alabama Board of Medical Examiners. |
The federal policy only answers the federal question. Each state now decides for itself, and the early answers point in opposite directions. Until a state speaks, the safer reading is that its existing law and board notices still apply.
- List every state you ship peptides into and record its current position, with a link to the source.
- Treat states with research grade peptide notices as unchanged unless the board says otherwise in writing.
- Ask each board how it wants the policy's state reports delivered, and keep the answer.
Licensure and Registration. The Licensure and Registration domain covers the state permits and board requirements a shipping pharmacy must meet. Peptide compounding now depends on each state's own position as well as the federal policy.
- Peptide Enforcement Discretion Policy PrimaryUtah Department of Commerce, Division of Professional LicensingRetrieved Nov 15, 2026
Announcement dated October 30, 2026; strict accordance with scope; each condition met.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances PrimaryAlabama Board of Medical Examiners and Medical Licensure CommissionRetrieved Nov 15, 2026
Board page reproducing the November 10, 2026 FSMB letter and FAQ.
- FAQs: HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances PrimaryFederation of State Medical Boards (hosted by the Alabama Board of Medical Examiners)Retrieved Nov 15, 2026
Questions 4 to 7: state law and board authority, 503A compliance references, physician compounding, state reporting.
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.